EP4122537A1 - Bridged Tricyclic Carbamoylpyridone Compounds
Summary
Gilead Sciences, Inc. has received EPO Publication EP4122537A1 for bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use, published on 15 April 2026. The application covers heterocyclic compounds with potential therapeutic applications, classified under IPC codes including C07D 471/04, C07D 491/06, and A61K 31/4375. The designation extends to 34 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.
“BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE”
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The EPO has published EP4122537A1, a patent application filed by Gilead Sciences, Inc. covering bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use. The application claims compounds classified under multiple C07D heterocyclic sub-classes and A61K pharmaceutical compositions, with potential therapeutic applications indicated by A61P 31/18 classification (likely antiviral). Eighteen inventors are named, including scientists from Gilead's medicinal chemistry department.
For pharmaceutical and biotech companies operating in Europe, this publication establishes a priority date and published claims that may overlap with existing R&D programmes in heterocyclic antiviral or anti-infective compounds. Companies developing similar carbamoylpyridone scaffolds should review the published claims for potential freedom-to-operate concerns upon national/regional phase entry in designated states.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
Publication EP4122537A1 Kind: A1 Apr 15, 2026
Applicants
Gilead Sciences, Inc.
Inventors
CHU, Hang, GONZALEZ BUENROSTRO, Ana Z., GUO, Hongyan, HAN, Xiaochun, JIANG, Lan, LI, Jiayao, MITCHELL, Michael L., PYUN, Hyung-Jung, SCHROEDER, Scott D., SCHWARZWALDER, Gregg M., SHAPIRO, Nathan D., SHIVAKUMAR, Devleena M., WU, Qiaoyin, YANG, Hong, ZHANG, Jennifer R.
IPC Classifications
A61P 31/18 20060101AFI20221027BHEP C07D 471/04 20060101ALI20221027BHEP C07D 491/06 20060101ALI20221027BHEP A61K 31/4375 20060101ALI20221027BHEP C07D 487/06 20060101ALI20221027BHEP C07D 487/08 20060101ALI20221027BHEP C07D 498/08 20060101ALI20221027BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.